Analyst says FDA forewarning to Gentium not an indictment, but investors flee
This article was originally published in Scrip
Executive Summary
While 18 August was a day of general panic on Wall Street over new fears of a global recession – with US, European and Asian markets all tanking –Gentium investors were additionally rattled on word that the company had voluntarily withdrawn its US application for its only clinical product, defibrotide, an experimental treatment for a potentially fatal complication related to stem cell transplants.